Gao Yan, Shen Jacson K, Milane Lara, Hornicek Francis J, Amiji Mansoor M, Duan Zhenfeng
Massachusetts General Hospital and Harvard Medical School, 55 Fruit St, Jackson Building Room 1115, Boston, MA 02114, USA.
Curr Med Chem. 2015;22(11):1335-47. doi: 10.2174/0929867322666150209151851.
Recent advances in cancer molecular biology have resulted in parallel and unprecedented progress in the development of targeted cancer therapy. Targeted therapy can provide higher efficacy and lower toxicity than conventional chemotherapy for cancer. However, like traditional chemotherapy, molecularly targeted cancer therapy also faces the challenge of drug resistance. Multiple mechanisms are responsible for chemotherapy resistance in tumors, including over-expression of efflux transporters, somatic alterations of drug targets, deregulation of apoptosis, and numerous pharmacokinetic issues. Nanotechnology based approaches are proving to be efficacious in overcoming drug resistance in cancer. Combination of targeted therapies with nanotechnology approaches is a promising strategy to overcome targeted therapy drug resistance in cancer treatment. This review discusses the mechanisms of targeted drug resistance in cancer and discusses nanotechnology approaches to circumvent this resistance.
癌症分子生物学的最新进展在靶向癌症治疗的发展中带来了并行且前所未有的进展。与传统化疗相比,靶向治疗可为癌症提供更高的疗效和更低的毒性。然而,与传统化疗一样,分子靶向癌症治疗也面临耐药性挑战。肿瘤化疗耐药有多种机制,包括外排转运体的过表达、药物靶点的体细胞改变、细胞凋亡失调以及众多药代动力学问题。基于纳米技术的方法在克服癌症耐药性方面已被证明是有效的。将靶向治疗与纳米技术方法相结合是克服癌症治疗中靶向治疗耐药性的一种有前景的策略。本综述讨论了癌症靶向耐药的机制,并探讨了规避这种耐药性的纳米技术方法。